News und Analysen

• 3 Bargain Stocks Under $20 With Major Growth Potential

NexGen Energy (NYSE:NXE) said its first quarter of 2026 marked a major transition point for the company, with Chief Executive Officer and

TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a

• Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation

• Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher

Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review

AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and

• Promising Upsides on these Biotech Penny Stocks

SAB Biotherapeutics (NASDAQ:SABS) said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the

Coherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data

• Biotech & Healthcare Meet AI: Stocks Soar On Innovation Potential

RadNet (NASDAQ:RDNT) reported record first-quarter 2026 revenue and adjusted EBITDA, with management saying demand for advanced

Stratec (ETR:SBS) reported a soft start to fiscal 2026, with first-quarter revenue and adjusted earnings down from the prior-year period, but management reaffirmed its full-year guidance and said

Globus Medical (NYSE:GMED) reported a strong start to 2026, with first-quarter revenue and earnings rising sharply as the company cited continued momentum in U.S. spine, margin expansion and

Genesis Energy (NYSE:GEL) said first-quarter 2026 results came in “a touch below” its internal expectations, primarily due to anticipated offshore producer turnarounds, lower-than-expected

Artivion (NYSE:AORT) executives said the company delivered double-digit revenue and adjusted EBITDA growth in the first quarter of 2026, while also lowering its full-year revenue outlook due

Verastem (NASDAQ:VSTM) reported first-quarter 2026 net product revenue of $18.7 million for AVMAPKI FAKZYNJA CO-PACK, as management said the launch of the therapy for KRAS-mutated recurrent

• 5 medical stocks growing earnings by triple digits

Vericel (NASDAQ:VCEL) reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage

• Down Over 80%, is Pet Insurer Trupanion Worth the Risk Premium?

Palomar (NASDAQ:PLMR) reported a strong start to 2026, with management highlighting broad-based premium growth, continued

BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing

• Deciphering Disruption: Inside Cathie Wood's Latest Plays

Pacific Biosciences of California (NASDAQ:PACB) reported first-quarter 2026 revenue of $37.2 million, roughly flat year over year, as

• 3 Under-the-Radar Healthcare Companies

Natera (NASDAQ:NTRA) reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a